Trials in Miami, Florida
Here are the top 10 medical studies for colorectal cancer in Miami, Florida
Popular Filters
Phase 3 Trials
Small Molecule
MRTX849 + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Miami, Florida
This trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Coral Gables, Florida
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Small Molecule Kinase Inhibitor
Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Miami Beach, Florida
This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.
Small Molecule Drug
Sotorasib + Panitumumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Miami Lakes, Florida
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
Chemotherapy Tailored by ctDNA Status for Colon Cancer
Recruiting1 awardPhase 2 & 3
Jonesboro, Arkansas
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Trials With No Placebo
Small Molecule
MRTX849 + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Miami, Florida
This trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
Virus Therapy
T3011 + Pembrolizumab for Advanced Cancers
Recruiting1 awardPhase 1 & 2
Plantation, Florida
This trial is testing a new drug, T3011, to see if it's safe and effective in treating people with advanced solid tumors. The study will also compare T3011 given alone to T3011 given with another drug, pembrolizumab.
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Coral Gables, Florida
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Miami, Florida
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Tyrosine Kinase Inhibitor
Fruquintinib + Tislelizumab for Solid Cancers
Recruiting1 awardPhase 1 & 2
West Palm Beach, Florida
This trial is testing a new cancer drug, fruquintinib, to see if it is safe and effective when used with tislelizumab to treat patients with locally advanced or metastatic solid tumors. The trial will be conducted in two parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2). Part 1 will be open to any-comer solid tumors and will determine the Recommended Phase 2 Dose (RP2D). The RP2D will be administered to four cohorts of patients in Part 2.
Cell Therapy
Immunotherapy with AlloStim for Metastatic Colorectal Cancer
Recruiting1 awardPhase 2
Miami Beach, Florida
This trial tests AlloStim, an immunotherapy using healthy donor immune cells, for patients with advanced colorectal cancer unresponsive to standard treatments. AlloStim helps train the patient's immune system to attack cancer cells by creating a temporary immune response.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.